Home โบ Paraganglioma
Paraganglioma clinical trials recruiting in the U.S.
14 studies for Paraganglioma are recruiting participants at sites across the United States.
Cities with the most studies
By state
Recently updated studies
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
RecruitingPhase 1
Ages 18 to 120 ยท All sexes ยท Updated Sep 29, 2026 ยท NCT06479811Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2ฮฑ Related Genetic Alterations (MK-6482-015)
RecruitingPhase 2
Ages 12 and older ยท All sexes ยท Updated Sep 25, 2026 ยท NCT04924075Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
RecruitingPhase 2
Ages 18 to 100 ยท All sexes ยท Updated Aug 25, 2026 ยท NCT03206060Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
RecruitingPhase 1/2
Ages 18 to 120 ยท All sexes ยท Updated Aug 18, 2026 ยท NCT06427798Using the EHR to Advance Genomic Medicine Across a Diverse Health System
Recruiting
Ages 18 and older ยท All sexes ยท Updated Aug 14, 2026 ยท NCT06377033Familial Investigations of Childhood Cancer Predisposition
RecruitingObservational study
All ages ยท All sexes ยท Updated Jun 17, 2026 ยท NCT03050268A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
RecruitingPhase 1
Ages 18 to 120 ยท All sexes ยท Updated Jun 15, 2026 ยท NCT06041516Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Jun 10, 2026 ยท NCT0728258718F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
RecruitingPhase 2
Ages 18 to 120 ยท All sexes ยท Updated May 19, 2026 ยท NCT06503146Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
RecruitingPhase 1/2
Ages 18 to 90 ยท All sexes ยท Updated May 14, 2026 ยท NCT05636618Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
RecruitingPhase 1
Ages 18 to 75 ยท All sexes ยท Updated Mar 17, 2026 ยท NCT04119024In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma
RecruitingEarly phase 1
Ages 18 and older ยท All sexes ยท Updated Feb 27, 2026 ยท NCT0563654068-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
RecruitingPhase 4
Ages 18 to 100 ยท All sexes ยท Updated Nov 21, 2025 ยท NCT04081701Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
RecruitingObservational studyHealthy volunteers welcome
All ages ยท All sexes ยท Updated Oct 15, 2025 ยท NCT03160274From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.